Calmodulin binding proteins and neuroinflammation in multiple neurodegenerative diseases

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Calcium dysregulation, known as the "Calcium Hypothesis," is an early event in neurodegenerative diseases.
• Calmodulin (CaM) is a key calcium-binding protein regulating hundreds of other proteins.
• The
• Calmodulin Hypothesis
• proposes that CaM-regulated proteins are central to Alzheimer's disease (AD) pathogenesis.

Purpose of the Study:

• To investigate the general applicability of the Calmodulin Hypothesis in neuroinflammation across multiple neurodegenerative diseases.
• To identify neuroinflammatory proteins that bind to calmodulin.
• To explore the therapeutic potential of targeting CaM-binding proteins.

Main Methods:

• Literature search for CaM binding.
• Bioinformatic analysis using the Calmodulin Target Database to scan 11 neuroinflammatory proteins for CaM binding domains.
• Integration of findings with previous research identifying 13 additional neuroinflammation-linked proteins.

Main Results:

• At least 24 critical neuroinflammatory proteins are identified as putative or proven calmodulin binding proteins.
• Eleven specific neuroinflammatory proteins (TREM2, CD33, PILRA, CR1, MS4A, CLU, ABCA7, EPHA1, ABCA1, CH3L1/YKL-40, NLRP3) were confirmed to have CaM binding domains.
• Many of these CaM binding proteins are implicated in multiple neurodegenerative diseases, including Alzheimer's, ALS, Huntington's, and Parkinson's disease.

Conclusions:

• Calmodulin binding proteins are central to neuroinflammatory processes in a wide range of neurodegenerative diseases.
• The findings support the Calmodulin Hypothesis's broad relevance beyond Alzheimer's disease.
• Calmodulin-based pharmaceuticals represent a promising therapeutic strategy for neurodegenerative diseases.